Jesús Piqueras Flores

Dr. Jesús Piqueras Flores

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Circulation
Verified
Journal Article
Open access
SHSoledad García Hernandez
Soledad García Hernandez
LRLuis de la Higuera Romero
Luis de la Higuera Romero
AFAdrian Fernandez
Adrian Fernandez
MPMaria Luisa Peña Peña
Maria Luisa Peña Peña
NMNerea Mora-Ayestaran
Nerea Mora-Ayestaran
JOJuan Pablo Ochoa
Juan Pablo Ochoa
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes, although recently certain nonsarcomeric genes have emerged as important contributors. Nonmendelian genetic variants with reproducible moderate-effect sizes and low penetrance, intermediate-effect variants (IEVs), can play a crucial role in modulating disease expression. Understanding the clinical impact of IEVs is crucial to unravel the complex genetic architecture of HCM. METHODS: We conducted an ancestry-based enrichment analysis of 14 validated HCM genes, including the 9 core sarcomeric and 5 nonsarcomeric genes (ALPK3 , CSRP3 , FHOD3 , FLNC , and TRIM63 ). Enrichment of intermediate frequency missense variants was evaluated in 10 981 patients with HCM, 4030 internal controls of European-ancestry, and 590 000 external controls from gnomAD non-Finnish Europeans. The population-attributable fraction was calculated to assess contribution of IEVs to HCM. Age-related disease penetrance, phenotypic severity (left ventricular maximum wall thickness), and major adverse cardiac events were analyzed in 11 991 HCM cases of the whole cohort according to 5 genetic groups: genotype negative, isolated IEV, monogenic, monogenic+IEV, and double monogenic. RESULTS: Fourteen IEVs in 8 genes were identified in 731 individuals (6.1% of the cohort), of whom 570 patients (4.8%) had IEVs in isolation: 198 (34.7%) in sarcomeric genes and 372 (65.3%) in nonsarcomeric genes. The contribution of IEVs to HCM genetics according to population-attributable fraction was estimated to be 4.9% (95% CI, 3.2–6.7). A significant gradient in penetrance, phenotypic severity, and major adverse cardiac events was observed across genetic groups. Compared with genotype-negative patients, IEV carriers displayed a younger median age at diagnosis (59 years of age [95% CI, 46–69] versus 61 years [95% CI, 49–70]; P =0.0073) and a higher mean left ventricular maximum wall thickness (18.1±3.7 versus 19.0±4.3; P =0.0043). IEVs also modified disease expression in individuals with monogenic variants, causing a more aggressive phenotype than in individuals from the monogenic-only group with HCM onset at younger age and a higher left ventricular maximum wall thickness (all P <0.0001), with major adverse cardiac event–free survival being significantly lower (93.3% versus 69.3% at 70 years of age; P <0.0001). CONCLUSIONS: IEVs are present in 6.1% of HCM cases and account for 4.8% of HCM genetic burden. IEVs also influence disease severity and outcomes, particularly when combined with monogenic disease-causing variants. Evaluation of IEVs should be considered when HCM genetic testing is performed.

30 May 2023 in Circulation
Verified
Journal Article
Closed access
FDFernando Domínguez
Fernando Domínguez
LLLaura Lalaguna
Laura Lalaguna
IMInés Martínez-Martín
Inés Martínez-Martín
JFJesús Piqueras Flores
Jesús Piqueras Flores
TRTorsten Bloch Rasmussen
Torsten Bloch Rasmussen
PGPablo García-Pavía
Pablo García-Pavía

20 November 2023 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Open access
DÁDaniel Águila‐Gordo
Daniel Águila‐Gordo
JJJavier Jiménez‐Díaz
Javier Jiménez‐Díaz
MNMartín Negreira‐Caamaño
Martín Negreira‐Caamaño
JRJorge Martínez‐Del Rio
Jorge Martínez‐Del Rio
CRCristina Ruiz‐Pastor
Cristina Ruiz‐Pastor
JFJesús Piqueras Flores
Jesús Piqueras Flores
Introduction: Electrical cardioversion (ECV) is a frequently used procedure for restoring sinus rhythm in atrial fibrillation (AF); however, the rate of recurrence is high. The identification of patients at high risk of recurrence could influence the decision‐making process. The present study evaluates the predictive value of risk scores in atrial fibrillation recurrence after elective electrical cardioversion.Methods: Unicentric, observational, and prospective study of adult patients who have undergone an elective ECV as rhythm control strategy between July 2017 and September 2022.Results: From the 283 analyzed patients (mean age 63.95 ± 10.76212, 74.9% male); 99 had paroxysmal AF (35%) and 159 (59%) presented AF recurrence during a follow‐up of 6 months. In patients with post‐ECV AF recurrence, the period of time from diagnosis until the performance of the procedure was longer (393 ± 891 vs. 195 ± 527, p = .02). No paroxysmal AF (71.3% vs. 57.8%, p = .02) and LA dilatation with >40 mL/m2 (35.9% vs. 23.3%, p = .02) volumes were more frequent within these patients. AF recurrence was more frequent in patients who had previous ECV (HR = 1.32; 95% CI: 1.12–2.35; p = .01) and more than 1 shock to recover sinus rhythm (HR = 1.62; 95% CI: 1.07–1.63; p = .01). The SLAC, ALARMEc, ATLAS, and CAAP‐AF scores were statistically significant, although with a moderate predictive capacity for post‐ECV recurrence.Conclusions: Risk scores analyzed showed a modest value predicting AF recurrence after ECV. Previous ECV, and greater difficulty in restoring SR were independent predictors of recurrence.

30 August 2023 in International Journal of Cardiology
Verified
Journal Article
Closed access
MNMartín Negreira-Caamaño
Martín Negreira-Caamaño
MRMarco Aurelio Ramírez-Huaranga
Marco Aurelio Ramírez-Huaranga
AGAna María García-Vicente
Ana María García-Vicente
MRMiguel Ángel Rienda-Moreno
Miguel Ángel Rienda-Moreno
POPaula Otero-Fernández
Paula Otero-Fernández
JFJesús Piqueras Flores
Jesús Piqueras Flores

19 December 2022 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
MNMartin Negreira-Caamaño
Martin Negreira-Caamaño
JRJorge Martínez-Del Río
Jorge Martínez-Del Río
AMAlfonso Morón-Alguacil
Alfonso Morón-Alguacil
PPPedro Pérez-Díaz
Pedro Pérez-Díaz
JFJesús Piqueras Flores
Jesús Piqueras Flores

30 December 2023 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
JFJesús Piqueras Flores
Jesús Piqueras Flores
EVEduardo Villacorta-Argüelles
Eduardo Villacorta-Argüelles
JGJoseph Galvin
Joseph Galvin
VCVicente Eduardo Climent
Vicente Eduardo Climent
LELuis Enrique Escobar-López
Luis Enrique Escobar-López
JOJuan Pablo Ochoa
Juan Pablo Ochoa
Formin homology 2 domain-containing 3 (FHOD3) gene has emerged as one of the main non-sarcomeric genes associated with hypertrophic cardiomyopathy (HCM), but no cases of biallelic variants associated with disease have been described to date. From 2014 until 2021, FHOD3 was evaluated in our center by next-generation sequencing in 22 806 consecutive unrelated probands. The p.Arg637Gln variant in FHOD3 was enriched in our HCM cohort (284 of 9668 probands; 2.94%) compared with internal controls (64 of 11 480; 0.59%) and gnomAD controls (373 of 64 409; 0.58%), with ORs of 5.40 (95% CI: 4.11 to 7.09) and 5.19 (95% CI: 4.44 to 6.07). The variant affects a highly conserved residue localised in a supercoiled alpha helix considered a clustering site for HCM variants, and in heterozygosis can act as a predisposing factor (intermediate-effect variant) for HCM, with an estimated penetrance of around 1%. Additionally, seven homozygous carriers of p.Arg637Gln in FHOD3 were identified. All but one (unaffected) showed an early presentation and a severe HCM phenotype. All this information suggest that p.Arg637Gln variant in FHOD3 is a low-penetrant variant, with an intermediate effect, that contributes to the development of HCM in simple heterozygosis, being associated with a more severe phenotype in homozygous carriers.